Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

NCT02872259 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT02872259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02872259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma
Lead sponsor
Haukeland University Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
February 13, 2017
Completion date
May 23, 2024
Enrollment
74 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma